Back to Search
Start Over
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.
- Source :
-
Journal of Parkinson's Disease . 2022, Vol. 12 Issue 2, p477-493. 17p. - Publication Year :
- 2022
-
Abstract
- Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treatment of the advanced stages of the illness. MAO-B inhibitors can effectively improve patients' motor and non-motor symptoms, reduce "OFF" time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy. [ABSTRACT FROM AUTHOR]
- Subjects :
- *PARKINSON'S disease
*DISEASE progression
Subjects
Details
- Language :
- English
- ISSN :
- 18777171
- Volume :
- 12
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Journal of Parkinson's Disease
- Publication Type :
- Academic Journal
- Accession number :
- 156139048
- Full Text :
- https://doi.org/10.3233/JPD-212976